Cargando…

Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial

INTRODUCTION: Current antibiotic prescription for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is generally based on the Anthonisen criteria in The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guideline that have a potential risk of antibiotics overuse....

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lixue, Wang, Jinxiang, Gu, Xiaoying, Sheng, Weili, Wang, Yeming, Cao, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344287/
https://www.ncbi.nlm.nih.gov/pubmed/34353802
http://dx.doi.org/10.1136/bmjopen-2021-049515
_version_ 1783734459695104000
author Huang, Lixue
Wang, Jinxiang
Gu, Xiaoying
Sheng, Weili
Wang, Yeming
Cao, Bin
author_facet Huang, Lixue
Wang, Jinxiang
Gu, Xiaoying
Sheng, Weili
Wang, Yeming
Cao, Bin
author_sort Huang, Lixue
collection PubMed
description INTRODUCTION: Current antibiotic prescription for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is generally based on the Anthonisen criteria in The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guideline that have a potential risk of antibiotics overuse. The dilemma is to identify patients who are most likely to benefit from antibiotics while avoiding unnecessary antibiotic use. Procalcitonin (PCT), a more sensitive and specific biomarker of bacterial infection than other conventional laboratory tests, has the potential to determine those patients in whom antibiotics would be beneficial. It is unclear whether PCT-guided antibiotic therapy is safe and effective for patients hospitalised with AECOPD. The study hypothesis is that PCT-guided antibiotic therapy could reduce the antibiotic prescription rate for AECOPD, compared with the GOLD guideline recommendations, without negatively impacting the treatment success rate. METHODS AND ANALYSIS: In this multicenter, open-label, randomised controlled trial, we aim to enrol 500 hospitalised patients with AECOPD that will be randomly assigned to either a PCT-guided group or a GOLD guideline-guided group. The coprimary endpoints are antibiotic prescription rate for AECOPD within 30 days post randomisation and treatment success rate at day 30 post randomisation. The secondary outcomes include: antibiotic prescription rate at day 1 post randomisation; hospital antibiotic exposure; length of hospital stay; rate of subsequent exacerbation and hospital readmission; overall mortality within 30 days post randomisation; changes in lung function and the score of COPD assessment test and modified Medical Research Council; and rate of intensive care unit admission. ETHICS AND DISSEMINATION: This trial has been approved by the ethic committee of China–Japan Friendship Hospital. The findings of the study will be disseminated in peer-reviewed journals. If the results of the study are positive, PCT-guided antibiotic therapy is likely to change the guidelines for antibiotic recommendations for patients with AECOPD. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT04682899.
format Online
Article
Text
id pubmed-8344287
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-83442872021-08-20 Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial Huang, Lixue Wang, Jinxiang Gu, Xiaoying Sheng, Weili Wang, Yeming Cao, Bin BMJ Open Respiratory Medicine INTRODUCTION: Current antibiotic prescription for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is generally based on the Anthonisen criteria in The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guideline that have a potential risk of antibiotics overuse. The dilemma is to identify patients who are most likely to benefit from antibiotics while avoiding unnecessary antibiotic use. Procalcitonin (PCT), a more sensitive and specific biomarker of bacterial infection than other conventional laboratory tests, has the potential to determine those patients in whom antibiotics would be beneficial. It is unclear whether PCT-guided antibiotic therapy is safe and effective for patients hospitalised with AECOPD. The study hypothesis is that PCT-guided antibiotic therapy could reduce the antibiotic prescription rate for AECOPD, compared with the GOLD guideline recommendations, without negatively impacting the treatment success rate. METHODS AND ANALYSIS: In this multicenter, open-label, randomised controlled trial, we aim to enrol 500 hospitalised patients with AECOPD that will be randomly assigned to either a PCT-guided group or a GOLD guideline-guided group. The coprimary endpoints are antibiotic prescription rate for AECOPD within 30 days post randomisation and treatment success rate at day 30 post randomisation. The secondary outcomes include: antibiotic prescription rate at day 1 post randomisation; hospital antibiotic exposure; length of hospital stay; rate of subsequent exacerbation and hospital readmission; overall mortality within 30 days post randomisation; changes in lung function and the score of COPD assessment test and modified Medical Research Council; and rate of intensive care unit admission. ETHICS AND DISSEMINATION: This trial has been approved by the ethic committee of China–Japan Friendship Hospital. The findings of the study will be disseminated in peer-reviewed journals. If the results of the study are positive, PCT-guided antibiotic therapy is likely to change the guidelines for antibiotic recommendations for patients with AECOPD. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT04682899. BMJ Publishing Group 2021-08-05 /pmc/articles/PMC8344287/ /pubmed/34353802 http://dx.doi.org/10.1136/bmjopen-2021-049515 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Respiratory Medicine
Huang, Lixue
Wang, Jinxiang
Gu, Xiaoying
Sheng, Weili
Wang, Yeming
Cao, Bin
Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial
title Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial
title_full Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial
title_fullStr Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial
title_full_unstemmed Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial
title_short Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial
title_sort procalcitonin-guided initiation of antibiotics in aecopd inpatients: study protocol for a multicenter randomised controlled trial
topic Respiratory Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344287/
https://www.ncbi.nlm.nih.gov/pubmed/34353802
http://dx.doi.org/10.1136/bmjopen-2021-049515
work_keys_str_mv AT huanglixue procalcitoninguidedinitiationofantibioticsinaecopdinpatientsstudyprotocolforamulticenterrandomisedcontrolledtrial
AT wangjinxiang procalcitoninguidedinitiationofantibioticsinaecopdinpatientsstudyprotocolforamulticenterrandomisedcontrolledtrial
AT guxiaoying procalcitoninguidedinitiationofantibioticsinaecopdinpatientsstudyprotocolforamulticenterrandomisedcontrolledtrial
AT shengweili procalcitoninguidedinitiationofantibioticsinaecopdinpatientsstudyprotocolforamulticenterrandomisedcontrolledtrial
AT wangyeming procalcitoninguidedinitiationofantibioticsinaecopdinpatientsstudyprotocolforamulticenterrandomisedcontrolledtrial
AT caobin procalcitoninguidedinitiationofantibioticsinaecopdinpatientsstudyprotocolforamulticenterrandomisedcontrolledtrial